Clal Biotechnology Industries Ltd. (TLV:CBI)
Israel · Delayed Price · Currency is ILS · Price in ILA 41.10
+3.80 (10.19%)
Sep 11, 2025, 5:26 PM IDT
TLV:CBI Income Statement
Financials in millions ILS. Fiscal year is January - December.
Millions ILS. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 0.09 | - | 0.1 | 0.37 | 0.22 | 0.21 | Upgrade | |
Revenue Growth (YoY) | -93.19% | - | -71.89% | 65.18% | 8.74% | -99.82% | Upgrade |
Gross Profit | 0.09 | - | 0.1 | 0.37 | 0.22 | 0.21 | Upgrade |
Selling, General & Admin | 5.24 | 6.35 | 9.76 | 12.27 | 12.22 | 10.3 | Upgrade |
Operating Expenses | 5.52 | 6.63 | 10.29 | 12.88 | 12.87 | 10.85 | Upgrade |
Operating Income | -5.43 | -6.63 | -10.18 | -12.51 | -12.65 | -10.64 | Upgrade |
Interest Expense | -0.29 | -3.57 | -3.54 | -3.73 | -1.76 | - | Upgrade |
Interest & Investment Income | 0.17 | 0.17 | 0.13 | 0.01 | - | - | Upgrade |
Earnings From Equity Investments | -13.36 | -28.57 | -17 | -22.39 | -30.81 | -28.94 | Upgrade |
Currency Exchange Gain (Loss) | 0.26 | 0.26 | 0.36 | 4.23 | -1.61 | -1.44 | Upgrade |
Other Non Operating Income (Expenses) | -0.22 | -0.74 | -0.86 | -2.31 | 11.38 | 103.03 | Upgrade |
EBT Excluding Unusual Items | -18.87 | -39.07 | -31.09 | -36.69 | -35.44 | 62.02 | Upgrade |
Gain (Loss) on Sale of Investments | -26.85 | -36 | 3 | -8.03 | -31.15 | 42.72 | Upgrade |
Gain (Loss) on Sale of Assets | - | - | - | - | - | 22.37 | Upgrade |
Other Unusual Items | - | - | - | 3.7 | - | - | Upgrade |
Pretax Income | -45.71 | -75.07 | -28.09 | -41.02 | -66.59 | 127.11 | Upgrade |
Earnings From Continuing Operations | -45.71 | -75.07 | -28.09 | -41.02 | -66.59 | 127.11 | Upgrade |
Earnings From Discontinued Operations | - | - | - | -54.41 | -61.63 | -77.27 | Upgrade |
Net Income to Company | -45.71 | -75.07 | -28.09 | -95.43 | -128.21 | 49.84 | Upgrade |
Minority Interest in Earnings | 14.17 | 12.62 | -2.96 | 33.69 | 38.63 | 59.19 | Upgrade |
Net Income | -31.55 | -62.46 | -31.05 | -61.74 | -89.58 | 109.03 | Upgrade |
Net Income to Common | -31.55 | -62.46 | -31.05 | -61.74 | -89.58 | 109.03 | Upgrade |
Shares Outstanding (Basic) | 153 | 158 | 157 | 157 | 158 | 161 | Upgrade |
Shares Outstanding (Diluted) | 153 | 158 | 157 | 157 | 158 | 161 | Upgrade |
Shares Change (YoY) | -12.84% | 1.02% | - | -1.01% | -1.74% | 0.01% | Upgrade |
EPS (Basic) | -0.21 | -0.39 | -0.20 | -0.39 | -0.57 | 0.68 | Upgrade |
EPS (Diluted) | -0.21 | -0.39 | -0.20 | -0.39 | -0.57 | 0.68 | Upgrade |
Free Cash Flow | -5.42 | -6.48 | -8.52 | -60.31 | -42.92 | -36.41 | Upgrade |
Free Cash Flow Per Share | -0.04 | -0.04 | -0.05 | -0.39 | -0.27 | -0.23 | Upgrade |
Dividend Per Share | - | - | - | - | - | 0.220 | Upgrade |
Gross Margin | 100.00% | - | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade |
Operating Margin | -5964.84% | - | -9789.42% | -3380.00% | -5645.09% | -5166.02% | Upgrade |
Profit Margin | -34664.83% | - | -29856.73% | -16686.49% | -39992.41% | 52925.73% | Upgrade |
Free Cash Flow Margin | -5952.75% | - | -8190.39% | -16300.00% | -19160.71% | -17675.24% | Upgrade |
EBITDA | -5.2 | -6.35 | -10.03 | 5.14 | 9.87 | 13.23 | Upgrade |
EBITDA Margin | - | - | - | 1388.38% | 4404.46% | 6420.39% | Upgrade |
D&A For EBITDA | 0.23 | 0.28 | 0.15 | 17.64 | 22.51 | 23.87 | Upgrade |
EBIT | -5.43 | -6.63 | -10.18 | -12.51 | -12.65 | -10.64 | Upgrade |
Revenue as Reported | 8.66 | 8.57 | 39.73 | 18.03 | 55.26 | 168.58 | Upgrade |
Updated Dec 31, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.